Solomon BJ, Liu G, Felip E, Mok TSK, et al. Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study. J Clin Oncol 2024 May 31:JCO2400581. doi: 10.1200/JCO.24.00581.
PMID: 38819031